<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax</dc:title><dc:creator>Avsec,	Damjan	(Avtor)
	</dc:creator><dc:creator>Škrlj,	Marja	(Avtor)
	</dc:creator><dc:creator>Burnik,	Tilen	(Avtor)
	</dc:creator><dc:creator>Kandušer,	Maša	(Avtor)
	</dc:creator><dc:creator>Bizjak,	Maruša	(Avtor)
	</dc:creator><dc:creator>Podgornik,	Helena	(Avtor)
	</dc:creator><dc:creator>Mlinarič-Raščan,	Irena	(Avtor)
	</dc:creator><dc:description>Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity. This is also true for the Bcl-2 antagonist venetoclax. We investigated the molecular mechanisms that drive venetoclax resistance in CLL, with a clear focus to provide new strategies to successfully combat it. Activation of CLL cells with IFNγ, PMA/ionomycin, and sCD40L diminished the cytotoxicity of venetoclax. We demonstrated that the metabolic activity of cells treated with 1 nM venetoclax alone was 48% of untreated cells, and was higher for cells co-treated with IFNγ (110%), PMA/ionomycin (78%), and sCD40L (62%). As of molecular mechanism, we showed that PMA/ionomycin and sCD40L triggered translocation of NFκB in primary CLL cells, while IFNγ activated p38 MAPK, suppressed spontaneous and venetoclax-induced apoptosis and induced formation of the immunoproteasome. Inhibition of immunoproteasome with ONX-0914 suppressed activity of immunoproteasome and synergized with venetoclax against primary CLL cells. On the other hand, inhibition of p38 MAPK abolished cytoprotective effects of IFNγ. We demonstrated that venetoclax-resistant (MEC-1 VER) cells overexpressed p38 MAPK and p-Bcl-2 (Ser70), and underexpressed Mcl-1, Bax, and Bak. Inhibition of p38 MAPK or immunoproteasome triggered apoptosis in CLL cells and overcame the resistance to venetoclax of MEC-1 VER cells and venetoclax-insensitive primary CLL cells. In conclusion, the p38 MAPK pathway and immunoproteasome represent novel targets to combat venetoclax resistance in CLL.</dc:description><dc:date>2022</dc:date><dc:date>2022-10-10 12:33:38</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>141876</dc:identifier><dc:identifier>UDK: 616.155.392</dc:identifier><dc:identifier>ISSN pri članku: 2041-4889</dc:identifier><dc:identifier>DOI: 10.1038/s41419-022-05287-6</dc:identifier><dc:identifier>COBISS_ID: 124912643</dc:identifier><dc:language>sl</dc:language></metadata>
